Daniel J. George

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial

  Prostate Cancer and Prostatic Diseases · 2026-06-20

• Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study

  Annals of Oncology · 2025-10-19 · 24 citations

• Comparison of Calcium-Containing Phosphate Binders vs. Noncalcium-Containing Phosphate Binders on Cardiovascular Outcomes: A Retrospective Cohort Study

  Journal of the American Society of Nephrology · 2025-10-01

• Multisystem Complications and Therapeutic Trends in Scleroderma Renal Crisis: Insight from a Five-Year Retrospective Cohort Study

  Journal of the American Society of Nephrology · 2025-10-01

• Abstract C116: Genetic ancestry concordant ceramide metabolism and response to androgen receptor pathway inhibition in metastatic castration-resistant prostate cancer

  Cancer Epidemiology Biomarkers & Prevention · 2025-09-18

• Abstract C117: Serum dehydroepiandrosterone sulfate (DHEAS) and race associated with longer survival in patients (pts) treated with apalutamide (Apa) and abiraterone acetate (AA) plus prednisone (P) in the PANTHER study

  Cancer Epidemiology Biomarkers & Prevention · 2025-09-18

• 2477P Real-world prostate-specific antigen (PSA) response with darolutamide or abiraterone in metastatic hormone-sensitive prostate cancer (mHSPC) triplet therapy

  Annals of Oncology · 2025-09-01

• Treatment Preferences among Patients with Hormone-Sensitive Prostate Cancer in France, Spain, China, South Korea, and Japan: A Discrete-Choice Experiment

  MDM Policy & Practice · 2025-07-01

• Mevrometostat in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate: The phase 3, randomized MEVPRO-1 study.

  Journal of Clinical Oncology · 2025-05-28

• Clinical outcomes of prompt versus deferred ¹⁷⁷ Lu-PSMA-617 initiation for metastatic castration-resistant prostate cancer (mCRPC) based on prior androgen receptor pathway inhibitor (ARPI) and taxane chemotherapy exposure: A real-world prostate cancer disease observation (PRECISION) data platform analysis.

  Journal of Clinical Oncology · 2025-05-28

• Overall survival outcomes with sipuleucel-T (Sip-T) among Black men with metastatic castrate-resistant prostate cancer (mCRPC) also treated with androgen receptor pathway inhibitors (ARPI).

  Journal of Clinical Oncology · 2025-05-28

• Ipilimumab and nivolumab in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated on the phase 3 PDIGREE (Alliance A031704) trial: Results from Step 1 analysis.

  Journal of Clinical Oncology · 2025-05-28 · 3 citations

• Real-world quality of life (QOL) in patients (pts) with metastatic renal cell carcinoma (mRCC) on active surveillance (AS) in the ODYSSEY prospective observational study.

  Journal of Clinical Oncology · 2025-05-28

• Predictive associations between serum dehydroepiandrosterone sulfate (DHEAS) and race among patients (pts) treated with apalutamide (apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study.

  Journal of Clinical Oncology · 2025-05-28

• Outcomes for patients with SPOP-mutated castration-resistant prostate cancer (CRPC) treated with an androgen receptor pathway inhibitor (ARPI).

  Journal of Clinical Oncology · 2025-05-28

• Ceramides and response to dual secondary hormonal therapy in metastatic castration-resistant prostate cancer (mCRPC) among Black men.

  Journal of Clinical Oncology · 2025-05-28

• Plain language summary: how long do patients with metastatic castration-resistant prostate cancer (mCRPC) live when taking abiraterone or enzalutamide in the real world?

  Future Oncology · 2025-04-25 · 1 citations

• Plain language summary: does race or income status affect the cancer treatments that patients with metastatic castration-sensitive prostate cancer (mCSPC) receive in the United States?

  Future Oncology · 2025-04-25

• IP26-09 REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER TREATED IN COMMUNITY UROLOGY CENTERS IN THE US: A COHORT STUDY USING THE PRECISION (PROSTATE CANCER DISEASE OBSERVATION) DATA PLATFORM

  The Journal of Urology · 2025-04-08

• Resilience and vulnerabilities of tumor cells under purine shortage stressPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-03-19 · 1 citations